BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Scil Proteins GmbH Receives €700K Research Grant from Investitionsbank Sachsen Anhalt


4/7/2011 9:30:06 AM

Halle, Germany, 7 April 2011 – Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, today announced that it has received an award of public funding to further establish methods for the combination of Affilin® therapeutics with biological effectors. The Investitionsbank Sachsen Anhalt has provided the Company with €700K to fund relevant in-house research projects.

Dr. Ulrike Fiedler, CEO of Scil Proteins, commented: “We are very pleased that the Investitionsbank Sachsen Anhalt has decided to continue and expand their support for our research endeavors to further develop our Affilin® therapeutics. The Bank has seen what we’ve achieved and that there’s significant potential for the development of the technology.”

Scil Proteins’ Affilin® therapeutics are so called scaffold proteins derived from the human serum protein Ubiquitin. Affilin® molecules are high affinity binders with excellent target specificity. The Affilin® platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months. Scil Proteins intends to advance into clinical development two Affilin® therapeutic candidates targeting cancer indications.

About Scil Proteins

Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins’ discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas. It also offers the technology to industry for collaborative discovery and development partnerships. With a longstanding expertise in protein production and development, Scil Proteins also offers GMP contract biomanufacturing and process development to biotech and pharma companies. Scil Proteins is a well-established private company located in Halle, Germany. To learn more about Scil Proteins please visit www.scilproteins.com

Contact

Frank Ubags

CFO

Scil Proteins GmbH

t: (Germany) +49 (0) 345 27 99 63 30

e: frank.ubags@scilproteins.om

Daniel Gooch - Senior Account Manager - London

Lauren McConville - Account Manager - Munich College Hill

t: (UK) +44 (0) 20 7866 7866

t: (Germany) +49 (0) 89 52 05 92 12

e: scilproteins@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES